Roughly one in three people diagnosed with major depressive disorder will not achieve remission even after multiple rounds of antidepressant therapy — a clinical reality often described as treatment-resistant depression, or TRD. In Washington State, where a growing mental health provider shortage has made specialist access increasingly difficult across Seattle and the broader Pacific Northwest, patients with TRD often cycle through years of medication trials before anyone introduces the question of whether a different class of treatment might be more appropriate. At Nomad Therapeutics, we work with patients who have reached that crossroads and deserve a clinical team willing to take their full history seriously.
Understanding the Neurobiology of Treatment-Resistant Depression
Treatment-resistant depression is not a character flaw or a failure of effort. It is a clinical designation that reflects the biological reality that depression is heterogeneous — different subtypes involve different neurobiological mechanisms, and the treatments that work for one subtype may be completely ineffective for another. The most widely used antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), work on monoaminergic systems. For patients whose depression involves significant dysregulation in glutamatergic pathways or inflammatory signaling, these drugs may simply not address the core problem — regardless of how many are tried or how carefully they are dosed.
This is the neurobiological context in which ketamine’s clinical utility becomes most clear. Ketamine acts primarily on NMDA glutamate receptors, a mechanism entirely distinct from SSRIs and SNRIs. Within hours of administration, it triggers a cascade of neuroplastic effects — including rapid increases in BDNF and the formation of new synaptic connections in the prefrontal cortex — that can produce antidepressant effects even in patients who have failed multiple previous treatments. Ketamine’s psychiatric use is off-label; the FDA has approved it as an anesthetic, not as a treatment for depression or any other psychiatric condition. However, the clinical evidence for ketamine in treatment-resistant depression is among the strongest of any emerging psychiatric intervention, and its speed of action — relief within hours rather than weeks — is clinically remarkable for patients who have been suffering for years.
How Nomad Therapeutics Evaluates TRD Patients
At Nomad Therapeutics, we begin every evaluation by mapping a patient’s full treatment history. We want to understand not only which medications have been tried but how long each was taken, at what doses, whether there were partial responses, what side effects emerged, and what the patient’s subjective experience of each treatment was. We also examine the diagnostic picture carefully: TRD presentations often involve comorbid anxiety, trauma history, OCD features, or borderline patterns that complicate response to standard care and need to be addressed within the treatment model rather than ignored.
Our team works with adults across a range of conditions ketamine treats, including treatment-resistant depression, PTSD, anxiety disorders, OCD, and related diagnoses that have not responded adequately to conventional care. Each patient is evaluated individually, and our intake process is designed to surface the full clinical picture before any treatment decisions are made.
The Clinical Advantages of At-Home Ketamine Therapy
Our at-home ketamine model carries specific clinical advantages for patients with severe or recurrent depression. When depression is acute, leaving the house can feel genuinely impossible — not an exaggeration but a neurobiological reality. A treatment that requires a patient to navigate traffic, find parking, and sit in a waiting room introduces friction at exactly the moments when friction is most costly. We eliminate that friction entirely. Our registered nurse comes to the patient’s home in the Seattle area, and the entire session takes place in a familiar, self-selected environment where the patient is as comfortable as they can be given their current state. Set and setting — the patient’s mindset and physical environment — are known to influence outcomes in ketamine therapy, and we take that evidence seriously in how we have structured our delivery model.
For patients who want to understand exactly what to expect before committing, our post on what to expect at your at-home ketamine session in Seattle walks through the full experience in practical terms — from arrival to the end of the session.
Addressing the Emotional Barriers to Seeking New Treatment
One significant barrier for many TRD patients seeking new treatment is the sense of defeat that accumulates after repeated treatment failures. We hear this often in intake conversations: patients who are deeply uncertain whether anything will help, who have modified their expectations downward year by year, and who approach a new treatment option with as much protective skepticism as genuine hope. We honor that skepticism. We do not promise outcomes we cannot guarantee. What we do promise is a thorough, honest evaluation that respects everything a patient has already been through, and a treatment model that is clinically coherent rather than speculative.
A second barrier involves the question of whether to tell a current psychiatrist or primary care provider about pursuing ketamine therapy. Some patients worry about their provider’s reaction or about disrupting a relationship they value. We encourage transparency where possible and always recommend that patients discuss all treatment options with their provider. Many psychiatrists in Seattle are familiar with ketamine-assisted psychotherapy and may actively support their patients pursuing evaluation. In cases where a patient’s current provider is less familiar with the evidence base, we are happy to provide clinical information and support that conversation. Results vary by individual, and the right treatment approach depends on the full clinical picture, which a patient’s existing providers help complete.
We work with adults in Seattle and the surrounding Pacific Northwest area who are living with treatment-resistant depression, major depressive disorder, PTSD, anxiety disorders, OCD, and related conditions. Our intake process is comprehensive, our communication is transparent, and our clinical model is grounded in the best available evidence for what helps when conventional treatment has not been enough.
Frequently Asked Questions
How is treatment-resistant depression defined clinically?
TRD is typically defined as a failure to achieve adequate response after at least two adequate antidepressant trials (correct medication, correct dose, sufficient duration). Some definitions require additional failed trials or specific symptom severity thresholds.
Can ketamine help if I have tried many antidepressants without success?
Ketamine works through a distinct mechanism from most antidepressants — specifically the glutamatergic system rather than serotonin or dopamine — which means it may be effective for patients who have not responded to SSRIs, SNRIs, or other monoamine-based treatments. Individual results vary, and evaluation is necessary to determine appropriateness.
Does Nomad Therapeutics treat conditions beyond depression?
Yes. Our team works with patients who have PTSD, anxiety disorders, OCD, bipolar depression, and related mental health conditions that have not responded adequately to conventional care. Each patient is evaluated individually.
Will my insurance cover at-home ketamine therapy?
Insurance coverage for ketamine therapy varies widely, and psychiatric ketamine use is off-label, which affects reimbursement. We recommend discussing financial options directly with our team during your initial consultation.
How quickly does ketamine work for treatment-resistant depression?
One of ketamine’s most clinically significant features is its speed. Many patients report meaningful mood improvement within hours to days of a session rather than the weeks typically required for antidepressants. Individual responses vary, and a single session is rarely the complete picture — a structured course of treatment produces more durable results.
Key Takeaways
- Treatment-resistant depression affects approximately one-third of people with MDD and reflects underlying neurobiological heterogeneity, not patient failure.
- Ketamine’s glutamatergic mechanism is distinct from most antidepressants, making it potentially effective for patients who have not responded to SSRI or SNRI treatment.
- Nomad Therapeutics’ at-home delivery model removes the logistical barriers that make clinic-based care especially difficult during acute depressive episodes.
- Every intake evaluation includes a thorough review of prior treatment history to build a clinically coherent, individualized plan.
- Results vary by individual; ketamine therapy is not appropriate for every patient, and honest evaluation is the starting point.
Take the First Step
Treatment-resistant depression is among the most debilitating conditions we encounter clinically, and it deserves more than another prescription that follows the same mechanism as the ones that have already failed. If you are in Seattle or the Pacific Northwest and have been living with depression that has not responded adequately to conventional care, we want to hear your story. Schedule a consultation with our team — an honest conversation about your history and your options is the first step toward a treatment plan that might finally work.
About Nomad Therapeutics
At Nomad Therapeutics in Seattle, our team delivers ketamine-assisted psychotherapy in the patient’s home, combining registered nurse–administered ketamine with preparation and integration therapy for a complete treatment model. We work specifically with patients who have not found adequate relief through conventional antidepressant treatment, starting every evaluation by taking the patient’s full history seriously and identifying what clinical picture it reveals. Our structured KAP model — preparation before each session, medication delivered by a nurse, and integration therapy afterward — is designed to make ketamine’s neuroplastic window translate into lasting therapeutic change for patients with treatment-resistant depression in the Seattle area.
Medical Disclaimer
The content on this page is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Ketamine therapy is not FDA-approved for psychiatric conditions including depression, anxiety, or PTSD; its use in these contexts is off-label and should be discussed thoroughly with a qualified healthcare provider. Results vary by individual, and no specific outcome is guaranteed. If you are experiencing a mental health crisis or emergency, please contact 988 (Suicide and Crisis Lifeline) or go to your nearest emergency room. Always discuss treatment options, risks, and benefits with your provider before making any healthcare decisions.
References
National Institute of Mental Health, Treatment-Resistant Depression: https://www.nimh.nih.gov/health/topics/depression
American Journal of Psychiatry, Ketamine for TRD: https://ajp.psychiatryonline.org/
Washington State Department of Health, Behavioral Health: https://doh.wa.gov/you-and-your-family/mental-health
Harvard Medical School, Ketamine for Depression: https://www.health.harvard.edu/blog/ketamine-for-major-depression-new-tool-new-questions-2019052216673